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PURPOSE. To evaluate the efficacy of osmoprotectants on prevention and treatment of dry eye
in a murine model.
METHODS. Dry eye was induced in mice by using an intelligently controlled environmental
system (ICES). Osmoprotectants betaine, L-carnitine, erythritol, or vehicle (PBS) were
topically administered to eyes four times daily following two schedules: schedule 1 (modeling
prevention): dosing started at the beginning of housing in ICES and lasted for 21 or 35 days;
schedule 2 (modeling treatment): dosing started after ICES-housed mice developed dry eye
(day 21), continuing until day 35. Treatment efficacy was evaluated for corneal fluorescein
staining; corneal epithelial apoptosis by TUNEL and caspase-3 assays; goblet cell numbers by
PAS staining; and expression of inflammatory mediators, TNF-a, IL-17, IL-6, or IL-1b by using
RT-PCR on days 0, 14, 21, and/or 35.
RESULTS. Compared with vehicle, prophylactic administration of betaine, L-carnitine, or
erythritol significantly decreased corneal staining and expression of TNF-a and IL-17 on day
21 (schedule 1). Treatment of mouse dry eye with osmoprotectants significantly reduced
corneal staining on day 35 compared with day 21 (schedule 2). Relative to vehicle, L-carnitine
treatment of mouse dry eye for 14 days (days 21 to 35) resulted in a significant reduction in
corneal staining, number of TUNEL-positive cells, and expression of TNF-a, IL-17, IL-6, or IL-
1b, as well as significantly increased the number of goblet cells.
CONCLUSIONS. Topical application of betaine, L-carnitine, or erythritol systematically limited
progression of environmentally induced dry eye. L-carnitine can also reduce the severity of
such dry-eye conditions.
Keywords: L-carnitine, betaine, osmoprotectants, dry eye, animal model, apoptosis,
inflammation, TNF-a, IL-17, IL-6, IL-1b
Dry-eye disease is one of the most common ophthalmicpathologies and is associated with tear film hyperosmolar-
ity and inflammation of the ocular surface.1 Osmolarity has
been reported to be highly correlated with severity of the
disease across normal, mild/moderate, and severe categories2
and can reach values of up to 360 mOsm3,4 compared with
normal tear film, which ranges between 300 and 310 mOsm.5 It
has been proposed that the tear film osmolarity over the ocular
surface can reach much higher values than is measured in
meniscus,6 and may reach values of up to 600 mOsm.7 Under a
hyperosmolar environment, cells will lose water and/or gain
salts, with concomitant changes in cell volume,8,9 leading to
damage to DNA and proteins,10 and induction of ocular surface
inflammatory responses.11 Tear film hyperosmolarity induces
hyperosmolarity of epithelial cells, unleashing a cascade of
inflammatory cytokines, such as IL-1, IL-6, IL-8, and TNF-a; and
proteolytic enzymes, such as matrix metalloproteinase-9 (MMP-
9).12,13 The production of inflammatory mediators on the
ocular surface has been suggested as the primary cause of
ocular discomfort, inflammation, and ocular surface cell
apoptosis.9,13,14
Hyperosmolarity-induced corneal epithelial apoptosis has
been observed using both cultured human ocular surface
epithelial cells and animal dry-eye models.15–21 Generally, cells
can adapt to a hyperosmotic environment by accumulating
compatible organic osmolytes/osmoprotectants.22 Osmopro-
tectants, such as L-carnitine and betaine, are compatible
solutes that act similarly to electrolytes to balance osmotic
pressure yet do not interfere with cell metabolism and can aid
survival of cells under extreme osmotic stress.9 L-carnitine and
erythritol have been shown to protect human corneal
epithelial cells in hyperosmotic conditions and to lower levels
of mitogen-activated protein (MAP) kinases in response to
hyperosmolar stress.23 L-carnitine and betaine also stabilize
corneal epithelial cell volume under hyperosmotic stress and
ameliorate hyperosmotic stress-induced human corneal epi-
thelial cell apoptosis (Garrett Q. IOVS 2012;53:ARVO E-
Abstract 564; Willcox MD. IOVS 2012;53:ARVO E-Abstract
564).24 Further, in dry-eye patients, reduced levels of tear L-
carnitine compared with healthy subjects have been report-
ed,25 suggesting that carnitine might play a contributory role
in the development of dry eye.
The intelligently controlled environmental system (ICES)-
induced murine dry eye model has been used previously to
assess therapeutic effects of trehalose eye drops.15,26 Continual
exposure of mice to the low humidity and excessive air flow
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created in ICES for 14 or more days promotes tear evaporation
that destabilizes the tear film and increases tear osmolarity,
showing biological and morphologic characteristics of dry eye
similar to those in humans, such as reduced aqueous tear
production, presence of corneal epithelial defects and
apoptosis of ocular surface epithelium, increased inflammatory
responses and expression of proteolytic MMP-9, as well as a
decrease in the number of goblet cells.15,26,27 Using this animal
model, the present study extended the previous in vitro studies
of osmoprotectants (Garrett Q. IOVS 2012;53:ARVO E-Abstract
564; Willcox MD. IOVS 2012;53:ARVO E-Abstract 564)23,24 to
determine the efficacy of osmoprotectants L-carnitine, betaine,
and erythritol in protection and therapeutic treatment of ICES-
induced murine dry eye.
TABLE. The Primer Sequences Used for qRT-PCR
Gene Forward Primer, 50–30 Reverse Primer, 50–30
IL-1b TGAGCTGAAAGCTCTCCACC CTGATGTACCAGTTGGGGAA
IL-6 AGATAACAAGAAAGACAAAGCCAGAGTC GCATTGGAAATTGGGGTAGGAAG
IL-17 CTCAACCGTTCCACGTCACCCT CCAGCTTTCCCTCCGCATT
TNF-a TCTACTGAACTTCGGGGTGATCG ACGTGGGCTACAGGCTTGTCA
GAPDH TGTCCGTCGTGGATCTGAC CCTGCTTCACCACCTTCTTG
FIGURE 1. Mean corneal staining score of mice in response to housing at ICES and topical treatment with betaine (0.23% in PBS), carnitine (0.25%
in PBS), erythritol (0.25% in PBS), or vehicle PBS, and ICES with no treatment, on days 0, 14, 21, and/or 35. (A) Schedule 1: compounds were
administered to mice at the beginning of their housing in ICES. *Statistically significant difference (P < 0.05) compared with the vehicle (PBS)
treatment on the same day (n¼22 for days 14 and 21; n¼10 for day 35). (B) Schedule 2: compound administration following housing in ICES for 21
days while mice were housed in ICES for a total of 35 days. *Statistically significant difference (P < 0.05) between day 21 and day 35 for the same
treatment group; #Statistically significant difference (P < 0.05) compared with the vehicle (PBS) treatment on day 35 (n¼ 18). Error bars present
the SD. (C, D) Representative corneal staining images after the treatment ([a], betaine; [b], L-carnitine; [c], erythritol; [d], PBS, or [e], ICES with no
treatment) for schedule 1, day 21 (C) or schedule 2, day 35 (D).
Osmoprotectants and Murine Dry Eye IOVS j September 2013 j Vol. 54 j No. 9 j 6288
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/932986/ on 01/23/2017
MATERIALS AND METHODS
Animals
All procedures were approved by the Animal Care and Ethics
Committee of Wenzhou Medical College, Zhejiang, China, and
adhered to the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research. Female C57BL/6 mice (age
range, 4–6 weeks, supplied by the Animal Breeding Unit of
Wenzhou Medical College) were used for this study. Only those
healthy mice with no corneal infections, infiltrations, or
leukoma, and with total scores of corneal fluorescein staining
less than 1027 were selected for the study.
ICES-Induced Murine Dry Eye Model
A murine model of dry eye was induced by an ICES.15,26,27 The
animals were maintained in relative humidity, 60% to 80%, no
airflow, and at 21 to 238C. Dry-eye desiccation was created
through exposure to relative humidity of 13.1% 6 3.5%,
airflow of 2.2 6 0.2 m/s, and temperature of 22 6 28C. After
housing for 21 days, mice began developing dry-eye conditions
similar to those observed in humans.26 The relative humidity
and temperature of ICES were monitored daily.
Compound Administration Schedules
Osmoprotectants for topical administration of betaine, L-
carnitine, and erythritol were formulated in sterile PBS. Mice
without any topical treatment were used as the dry-eye
control group (ICES), whereas PBS-treated mice were the
vehicle control (PBS). Two topical administration schedules
were used for this study: schedule 1 was designed to model
prevention in which dosing of a compound started at the
beginning of housing in the ICES (on day 1) and lasted for 21
or 35 days; whereas schedule 2 was to model treatment
where dosing started on day 22 after the housed mice
developed dry eye (on day 21)26 and lasted until day 35.
During both schedules, mice remained housed in ICES. In
both schedules, 10 lL per eye of each compound solution
was topically administered to mice eyes bilaterally four times
a day. Five treatment groups were classified as follows:
betaine (0.23% in PBS), L-carnitine (0.25% in PBS), erythritol
(0.25% in PBS), PBS only, and no treatment (ICES), respec-
tively. Five animals were used per treatment group. PBS was
from Maixin Technology (Fujian, China) and betaine, L-
carnitine, erythritol were all from Sigma-Aldrich (Shanghai,
China). The concentrations of the test compounds were
determined based on the previously published data where
addition of L-carnitine (10–15 mM), erythritol (20–40 mM), or
betaine (10 mM), to hyperosmolar media demonstrated
osmoprotection of cultured human corneal epithelial
cells.23,24 As well, the addition of betaine or L-carnitine at
10 mM, or erythritol at 40 mM, to the culture medium had no
effect on viability of the cultured corneal epithelial cells.23
Clinical Examination: Corneal Fluorescein
Staining
Clinical examination using corneal fluorescein staining was
performed on all eyes on days 0, 14, 21, and 35 by instilling via
a micropipette 0.5 lL of 5% fluorescein PBS solution into the
inferior conjunctival sac. The cornea was examined using a slit-
lamp microscope (SLM-3; Kanghua Technology Co., Ltd.,
Chongqing, China) with cobalt blue light after fluorescein
instillation. The stained area was assessed and graded by a
masked observer using the 2007 Dry Eye WorkShop (DEWS)-
recommended grading system.28 Mouse corneas were rated
from 0 to 4, with the cornea surface divided into five regions (0
dot, Grade 0; 1–5 dots, Grade 1; 6–15 dots, Grade 2; 16–30
dots, Grade 3; and 30 dots, Grade 4). The total score from the
five regions was recorded.
Animal Euthanasia
For schedule 1, at the end time point of day 21 in ICES
(schedule 1, day 21), mice from each group were killed with an
overdose of a mixture of ketamine and xylazine for histological,
immunohistochemical, and quantitative RT-PCR (qRT-PCR). For
schedule 2, a subset of mice from ICES control was killed at day
21 and other mice were killed on day 35 (schedule 2, day 35).
Additional healthy animals not housed in ICES and receiving no
treatment were euthanized as untreated healthy controls for
comparison.
FIGURE 2. Corneal epithelium of the normal healthy mice or the ICES-housed mice with or without the treatment with betaine (A), L-carnitine (B),
erythritol (C), PBS (D), or with no treatment (E), for schedule 1, day 21 and schedule 2, day 35 (magnification: 340).
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PAS Staining of Goblet Cells
After animals were killed, eyes and ocular adnexa were
surgically excised, fixed in 10% formalin, paraffin embedded,
and cut into 8-lm sections. The bulbar conjunctival epithelium
(superior and inferior regions) sections were stained with PAS
(Sigma-Aldrich) reagent for measuring goblet cells and were
examined and photographed with a microscope equipped
with a digital camera (BX51; Olympus, Guangzhou, China).
PAS-positive goblet cells in the conjunctiva were measured in
five sections from each eye with image analysis software
(available in the public domain at http://rsb. info.nih.gov/ij/
index.html; ImageJ software; developed by Wayne Rasband,
National Institutes of Health, Bethesda, MD).
Apoptosis
Immunohistochemical evaluation of caspase-3 expression and
TUNEL assay were performed on corneal tissues collected on
schedule 1, day 21, and schedule 2, day 35, to detect apoptosis
of the corneal epithelial cells. The expression of caspase-3 was
evaluated by laser scanning confocal microscopy (LSM 710;
Zeiss with krypton-argon and He-Ne laser; Carl Zeiss Meditec,
Sartrouville, France) using frozen corneal tissue sections. Mice
eyes (schedule 1, day 21, and schedule 2, day 35) from each
treatment group were excised. Corneal section slides were
fixed with methanol at 48C for 10 minutes. After fixation, they
were permeabilized with Triton X-100 (0.25% Triton X-100 in
PBS) for 10 minutes and then blocked with 10% goat serum in
PBS for 60 minutes. Caspase-3 antibody (1:100 dilution; Abcam,
Cambridge, MA) was applied and incubated for 12 hours at 48C
followed by incubation with secondary antibody (Alexa-Fluor
594-conjugated goat anti-rabbit IgG, 1:300; Invitrogen-Molecu-
lar Probes, Eugene, OR) in a dark chamber for 1 hour at room
temperature. Counterstaining with 40,6-diamidino-2-phenylin-
dole (DAPI; 1:1000 dilution) was followed for 10 minutes.
Sections were covered with Slowfade antifade mounting
medium (Invitrogen, Eugene, OR) and sealed with a cover slip
for microscopic observation.
DNA fragmentation detected by TUNEL assay was also
evaluated using laser scanning confocal microscopy and frozen
corneal tissue sections. Mice eyes (schedule 1, day 21, and
schedule 2, day 35) from each treatment group were excised.
Corneal section slides were fixed with 4% paraformaldehyde in
PBS at room temperature for 10 minutes. After fixation, they
were permeabilized with Triton X-100 (0.1% in PBS; Sigma, St.
FIGURE 3. Bulbar conjunctival epithelium (superior, magnification:340; scale bar: 50 lm) with expression of goblet cells (pink, positive to PAS
staining) in response to (I) housing at ICES for 21 days with the schedule 1 treatment during which compounds were administered to mice at the
beginning of their housing; or (II) housing in ICES for 35 days with schedule 2 treatment during which compound administration began following
mouse housing in ICES for 21 days. The treatment groups are (A): betaine (0.23% in PBS), (B): L-carnitine (0.25% in PBS), (C): erythritol (0.25% in
PBS), and (D): PBS. Mice housed in ICES with no treatment (E) and normal healthy mice without housing in ICES or receiving any treatment were
used as comparisons. Graphs demonstrate the average number of goblet cells 6 SD in both superior and inferior regions. *Statistically significant
difference compared to the vehicle PBS (P < 0.05, n¼6). †Statistically significant difference of the ICES-housed mice between no treatment and the
treatment with betaine, L-carnitine, erythritol, or PBS (P < 0.05, n ¼ 6); #Statistically significant difference between the normal healthy mice and
other groups (P < 0.05, n ¼ 6). Error bars present SD.
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Louis, MO) for 10 minutes and then 50 lL (5 lL enzyme
solution in 45 lL label solution) TUNEL reaction mixture (In
Site Cell Death Detection Kit; Roche, Mannhein, Germany) was
applied and incubated for 1 hour at 378C in a humidified
atmosphere. Counterstaining with DAPI (1:1000 dilution) was
followed for 30 minutes. Sections were covered with antifade
mounting medium and sealed with a cover slip for microscopic
observation.
Inflammatory Responses
qRT-PCR was used for detection of the expression of IL-1b, IL-6,
IL-17, TNF-a, and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Total RNA from conjunctivas was extracted and
pooled from two eyes of the same experimental group and
same compound administration schedule using the RNA
isolation kit according to the manufacturer’s instructions
(PicoPure RNA isolation kit; Applied Biosystem, Foster City,
CA). cDNA was synthesized from 1 lg total RNA using random
primers and Moloney Murine Leukemia Virus (M-MuLV) reverse
transcriptase. The primer sequences for qRT-PCR detection of
the inflammatory mediators of interest are listed in the Table.
The RNA concentration was measured at 260 nm and stored at
808C before use. qRT-PCR analysis was employed by using the
SYBR Green PCR Core Reagents System (Applied Biosystems,
Paisley, UK) and Applied Biosystems 7500 Real-Time PCR
System (Applied Biosystems). Assays were performed in
duplicate and repeated three times. The qRT-PCR results were
analyzed using the comparative threshold cycle method and
normalized with GAPDH as an endogenous reference.
Statistical Analysis
The 2(-Delta Delta C[T]) method29 was used to analyze the
relative changes in gene expression from real-time RT-PCR
experiments. Statistical comparisons of four treatment groups
and the group without treatment (ICES) for real-time PCR were
performed with ANOVA. Post hoc multiple comparisons were
adjusted using Tukey correction. The Mann-Whitney U test
was used to compare the controls and the treatment groups for
mouse corneal fluorescein staining scores. P less than 0.05 was
considered statistically significant. Analyses were performed
using SPSS 13.0 software (IBM SPSS Statistics, IBM Corporation,
Chicago, IL).
FIGURE 4. Confocal microscopic observation of caspase-3 expression in mouse corneas (green, caspase-3–positive; blue, DAPI-positive cells) in
response to (I) housing in ICES for 21 days with the schedule 1 treatment in which compounds were administered to mice at the beginning of
housing in ICES; or (II) housing in ICES for 35 days with schedule 2 treatment in which compound administration began following housing in ICES
for 21 days. The treatment groups are (A): betaine (0.23% in PBS); (B): carnitine (0.25% in PBS), (C): erythritol (0.25% in PBS), and (D): PBS. Mice
housed in ICES with no treatment (E) and normal healthy mice without housing in ICES or receiving any treatment were used as comparisons
(magnification: 320; scale bars: 50 lm). Error bars present SD.
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RESULTS
Corneal Fluorescein Staining
Fluorescein staining was used to assess changes in corneal
epithelial integrity. For schedule 1, all three osmoprotectants
(betaine, L-carnitine, or erythritol) reduced corneal staining on
day 21 compared with the vehicle PBS and the ICES control
receiving no treatment (P < 0.05) (Figs. 1A, 1C). Reduced
corneal staining was also evident on day 14 for betaine- or L-
carnitine–treated mice; on day 35, L-carnitine treated mice
corneas still exhibited significantly lower staining compared
with the PBS control and ICES (Figs. 1A, 1C).
For schedule 2, Figures 1B and 1D show mouse corneas
treated with betaine, L-carnitine, or erythritol for 14 days,
following 21 days of desiccating conditions (by which time
mice displayed typical signs of dry eye). All compounds
demonstrated therapeutic action with significant reductions in
mean corneal staining on day 35 compared with day 21 (P <
FIGURE 5. Apoptosis of the mouse ocular surfaces (green, positive to TUNEL staining) in response to (I) housing in ICES for 21 days using the
schedule 1 treatment in which compounds were administered to mice at the beginning of their housing in ICES; or (II) housing in ICES for 35 days
using schedule 2 treatment in which compound administration began following housing in ICES for 21 days. The treatment groups are betaine ([A],
0.23% in PBS), carnitine ([B], 0.25% in PBS), erythritol ([C], 0.25% in PBS), and PBS vehicle (D). Mice housed in ICES with no treatment (E) and
normal healthy mice without housing in ICES or receiving any treatment were used as comparisons (magnification:320; scale bars: 50 lm). Graphs
demonstrate the mean 6 SD of apoptotic cell density (number of cells/100 lm). *Statistically significant difference compared with vehicle PBS (P <
0.05, n ¼ 6). †Statistically significant difference of the ICES-housed mice between no treatment and the treatment with betaine, L-carnitine,
erythritol, or PBS (P < 0.05, n¼ 6). #Statistically significant difference between the normal healthy mice and other groups (P < 0.05, n¼ 6). Error
bars present SD.
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0.05). Corneas treated with L-carnitine or erythritol showed
significant reduction in mean corneal staining relative to
vehicle PBS on day 35. Betaine showed some effect in reducing
corneal staining, but the effect was not significantly different
compared with PBS (P ¼ 0.252) on day 35. No statistically
significant difference was found between PBS and ICES on day
21 or day 35.
Morphology of the Corneal Epithelium
Corneal epithelium thinning in the mice eyes after housing in
ICES for 21 or 35 days was observed (Fig. 2E) compared with
the normal healthy mice eyes (Fig. 2 normal). Although slight
thinning was observed in all the treatment groups (Figs. 2A–D)
for both schedule 1, day 21, and schedule 2, day 35, the ICES-
housed, untreated mice showed greater thinning compared
with the treatment or normal mice: from 32.7 6 1.1 lm to
24.3 6 2.1 lm and 23.5 6 1.2 lm (normal to ICES housed) for
schedule 1, day 21, and schedule 2, day 35, respectively.
Conjunctival Goblet Cells
For both schedule 1, day 21 (Fig. 3 [I]) and schedule 2, day 35
(Fig. 3 [II]), there was a significant reduction in the number of
goblet cells for all the ICES-housed mice (with or without
treatments) compared with normal healthy mice that had not
been housed in ICES or received any treatment (all P < 0.05).
The ICES-housed mice presented with increased numbers of
goblet cells after receiving the treatment with betaine, L-
carnitine, erythritol, or vehicle PBS relative to those with no
treatment (Fig. 3, all P < 0.05). Although an increasing trend in
goblet cell number was observed with betaine or erythritol,
only L-carnitine treatment showed significantly increased
goblet cell numbers compared with the vehicle PBS control
(Fig. 3, P¼ 0.0001 [superior], 0.0002 [inferior] for schedule 1,
day 21, and P ¼ 0.0001 [superior and inferior] for schedule 2,
day 35, respectively).
Apoptosis: Caspase-3 Expression
Immunohistochemistry for caspase-3 expression (green stain-
ing) in the corneal epithelium revealed much reduced
immunoreactivity (similar to the level in normal healthy mice)
under schedule 1 following daily treatment with each
osmoprotectant, betaine (A), L-carnitine (B), or erythritol (C),
compared with the treatment vehicle PBS (D) , or with no
treatment (ICES, E) (Fig. 4 [I]). For schedule 2, on day 35, the L-
carnitine–treated mice (Fig. 4 [IIB]) presented similar immune
reactivity of caspase-3 compared with the normal healthy mice,
whereas for betaine (A), erythritol (C), or ICES (E), immune
reactivity of caspase-3 was not reduced relative to PBS control.
Apoptosis: TUNEL Staining
Figure 5 shows that all the ICES-housed mice, with or without
treatment, had a significantly higher number of apoptotic cells
(positive to TUNEL staining; green) compared with the
unhoused normal healthy mice on day 21, schedule 1 and
day 35, schedule 2 (all P < 0.05). Furthermore, a significant
reduction in the number of ICES-induced apoptotic cells was
observed by day 21, schedule 1, in corneas that had received
daily administration of the osmoprotectants or PBS vehicle (Fig.
FIGURE 6. Real-time PCR analysis of TNF-a (A), IL-17 (B), IL-6 (C), and IL-1b (D) expression after mice were housed in ICES for 21 days using the
schedule 1 treatment in which compounds (0.23% betaine in PBS, 0.25% carnitine in PBS, 0.25% erythritol in PBS, or PBS vehicle) were administered
to mice at the beginning of their housing in ICES. Mice housed in ICES with no treatment and normal healthy mice without housing in ICES or
receiving any treatment were used as comparisons. *Statistically significant difference compared with the vehicle PBS (P < 0.05, n¼3). †Statistically
significant difference compared with the ICES control (P < 0.05, n¼ 3). #Statistically significant difference between the normal healthy mice and
other groups (P < 0.05, n ¼ 3). Error bars present SD.
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5 [I], P < 0.001). There was a further reduction, relative to
PBS, in apoptotic cell density with all the osmoprotectant
treatments on day 21, schedule 1, and on day 35, schedule 2;
however, this reduction reached statistical significance only for
the L-carnitine treatment group (P ¼ 0.032 and 0.0005, Fig. 5
[I] and [II], respectively).
Inflammatory Responses
qRT-PCR was used to evaluate TNF-a, IL-17, IL-6, and IL-1b
mRNA expression levels (Fig. 6 for schedule 1, day 21; Fig. 7 for
schedule 2, day 35). For both schedules, mRNA expression for
each inflammatory mediator was significantly higher in the
conjunctiva of all the ICES-housed mice than those in the
unhoused normal healthy mice (P < 0.01, Figs. 6, 7). L-
carnitine treatment in both schedules showed a statistically
significant reduction in expression level of each mediator,
relative to the vehicle PBS samples, as well as to the other
treatment groups, betaine and erythritol (all P < 0.05, Figs. 6,
7). Furthermore, compared with the ICES control with no
treatment, systematic administration of osmoprotectants (be-
taine, L-carnitine, or erythritol), starting at the beginning of
housing in the ICES, significantly reduced the expression level
of TNF-a, IL-17, IL-6, and IL-1b (Fig. 6, all P < 0.05). Compared
with the vehicle PBS, expression of TNF-a and IL-17 was
significantly reduced by the treatment with each osmoprotec-
tant (Fig. 5, all P < 0.05). For schedule 2, day 35, treatment
with each of the osmoprotectants significantly reduced
expression of TNF-a, IL-17, and IL-6 compared with the ICES
control with no treatment (Fig. 7, all P < 0.05). Betaine, L-
carnitine, or erythritol treatment also significantly reduced
TNF-a expression relative to vehicle PBS (Fig. 7, P < 0.05), but
not the expression of IL-17, IL-6, and IL-1b.
DISCUSSION
In the present study, we used a murine dry eye model to
evaluate the efficacy of prophylactic and therapeutic treatment
of L-carnitine, betaine, and erythritol in maintaining and
restoring ocular surface health in a desiccating environment
created by ICES. We showed that systematic administration
with these compounds during the establishment of murine dry
eye (by housing in ICES) limited desiccation-induced clinical
signs of dry eye, ocular surface inflammatory responses, and
apoptosis. We also showed that on onset of mouse dry-eye
conditions, systematic treatment with L-carnitine, or to a lesser
extent, with betaine or erythritol, attenuated the deleterious
effects by reduction of corneal staining, ocular epithelial cell
apoptosis, and expression of TNF-a, IL-17, IL-6, and IL-1b, as
well as maintaining the number of PAS-positive conjunctival
goblet cells, thus demonstrating the potential of L-carnitine not
only in the prevention but also in the therapeutic treatment of
dry eye.
Epitheliopathy is one of the most easily recognizable clinical
features of dry-eye disease. Environmental desiccation stress-
induced dry-eye conditions decrease epithelial cell size and
increase epithelial cell turnover.30 Staining the ocular surface
with diagnostic dyes, such as fluorescein, provides a practical
method for evaluating ocular surface integrity. Treatment with
betaine, L-carnitine, or erythritol during the development of
FIGURE 7. Real-time PCR analysis of TNF-a (A), IL-17 (B), IL-6 (C), and IL-1b (D) expression after mice housing in ICES for 35 days using schedule 2
treatment in which compound administration began following housing in ICES for 21 days. The treatment groups are betaine ([A], 0.23% in PBS);
carnitine (0.25% in PBS), erythritol (0.25% in PBS), or PBS vehicle. Mice housing in ICES with no treatment and normal healthy mice without
housing in ICES or receiving any treatment were used as comparisons. *Statistically significant difference compared with the vehicle PBS (P < 0.05,
n¼3). †Statistically significant difference compared with the ICES control (P < 0.05, n¼3). #Statistically significant difference between the normal
healthy mice and other groups (P < 0.05, n ¼ 3). Error bars present SD.
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dry eye reduced corneal staining once dry-eye conditions were
established (day 21). These observations suggest that osmo-
protectants might help maintain and protect murine ocular
surface integrity from ICES desiccation-induced damage. A
similar effect was also observed with the L-carnitine or
erythritol treatment of the mice whose condition of dry eye
was already developed (housing in ICES for 21 days) before
systematic treatment (for 14 days), suggesting that these
compounds could also help to restore mouse ocular surface
health.
Mucins released into the tear film are crucial for maintaining
a healthy ocular surface.31,32 Hyperosmolarity in dry eye can
induce cornification of conjunctival epithelial cells, entrapping
the goblet cells, blocking mucus secretion, and subsequently
degrading tear quality and stability.33 Goblet cell populations
are suggested to be sensitive indicators of ocular surface
disease.34 In our study, L-carnitine restored (although not
completely) the loss of PAS-positive goblet cells caused by ICES
desiccation (schedule 1) and dry eye conditions (schedule 2).
Kunert et al.34 similarly reported an increase (relative to
untreated controls) in goblet cell density on treatment of dry
eye syndrome with topical application of cyclosporin, suggest-
ing that the anti-inflammatory properties of cyclosporin
reduced ocular surface inflammation and concomitantly
restored goblet cell density. That we observed similar increased
goblet cell density with L-carnitine therapy suggests an
additional influence of L-carnitine on reducing ocular surface
inflammation.
It is recognized that inflammation plays a prominent role in
the development and magnitude of signs and symptoms of dry
eye. Tear hyperosmolarity and intracellular signaling pathway
activation induced by desiccating stress initiate the production
of proinflammatory cytokines, such as IL-1, IL-6, IL-8, and TNF-
a, and proteolytic enzymes, such as MMP-9.18,35,36 Using the
same ICES murine dry-eye model, we previously reported dry-
eye–associated increased ocular surface inflammation (a
hallmark of dry-eye disease) as indicated by increased
expression of IL-1b, TNF-a, IL-6, and IL-17.26 Application of
trehalose eye drop restored ocular integrity in this model,
reducing expression of IL-17, which in turn reduced the IL-17–
mediated expression of IL-1, TNF-a, and IL-6.26 That TNF-a, IL-
17, IL-6, and IL-1b were similarly upregulated in ICES controls
in the present study further supports the use of the ICES model
to mimic physiological stress experienced in dry eye. Activated
MAP kinases can initiate expression of transcription factors,
leading to expression of inflammatory cytokines, chemokines,
and MMPs.37 Epithelial and inflammatory cell production of
MMP-9, stimulated by IL-1 and TNF-a, is suggested to impede
reepithelialization of the cornea after injury.38,39 Previous
studies have shown the osmoprotectants L-carnitine and
erythritol, alone or in combination, can reduce the activa-
tion/phosphorylation of MAP kinases in cultured human
corneal epithelial cells in response to hyperosmolar stress.23
Reduced expression of MAP kinases would reduce production
of MMP-9, suppressing the innate immune responses associat-
ed with expression of IL-1, TNF-a, and IL-17. In the present
study, continual treatment of mice with betaine, L-carnitine, or
erythritol suppressed expression of proinflammatory cytokines
during the development of dry eye, as well as in dry-eye mice
whose dry-eye conditions were developed before the treat-
ment. This indicates that these compounds were able to at
least partially ameliorate the inflammatory responses, consis-
tent with previous reports of the anti-inflammatory properties
of L-carnitine and betaine.40,41 It should be noted that among
all the compounds, L-carnitine presented the only statistically
significant, and the most beneficial effect, on lowering
inflammatory responses of all the mediators investigated and
demonstrated in both schedules.
L-carnitine is essential in maintaining the health of cells42
and is best known for its important role in the mitochondrial
oxidation of long-chain fatty acids.42–44 Reports further
indicate that L-carnitine also possesses anti-inflammatory and
immunosuppressive activities.40,41 An in vivo study using a
murine model of Crohn’s disease revealed that systemic
administration/treatment with L-carnitine during the establish-
ment of colonic inflammation successfully reduced cytokine
production and intestinal inflammation, and this protection
was associated with a suppressive effect of L-carnitine on the
colonic mRNA expression and serum of IL-1b and IL-6.43 In
humans, an immunosuppressive role of L-carnitine is also
observed with reduction of TNF-a levels in surgical and AIDS
patients after receiving L-carnitine supplementation.45,46 Like
L-carnitine, betaine has also been reported to possess anti-
inflammatory properties.38 Although the molecular events
associated with the anti-inflammatory effects of L-carnitine or
betaine in dry eye are not yet fully understood, we have
demonstrated these activities also play a role in prevention and
treatment of murine dry eye.
Long-term exposure of eyes to a desiccating environment
increases tear evaporation, leading to hyperosmolarity. In an
experimental mouse model of dry-eye disease, desiccating
stress increased mouse tear osmolarity nearly 2-fold.47 Hyper-
osmolarity is known to induce ocular surface epithelial
apoptosis both in vitro (Garrett Q. IOVS 2011;52:ARVO E-
Abstract 290-D754; Garrett Q. IOVS 2012;53:ARVO E-Abstract
564; Willcox MD. IOVS 2012;53:ARVO E-Abstract
564)16,24,19,48–54 and in vivo.13,26 In the present study, we also
observed corneal epithelial apoptosis in ICES-induced murine
dry eyes. However, treatment with osmoprotectants, in
particular L-carnitine, appears to limit the ICES housing–
induced apoptosis and contributes to stabilization of the ocular
cell in the presence of desiccating conditions (although not
completely). Although regulatory volume increase, the initial
protective response to hypertonic induced cell shrinkage,
restores cell volume within minutes through rapid uptake of
inorganic ions,55 the concentration of intracellular ions and,
consequently, the intracellular ionic strength, remain abnor-
mally high, which perturbs intracellular macromolecules.56
However, if compatible organic osmolytes are available, they
can enter and accumulate in cells and lower the ionic strength
toward the isotonic state while maintaining cell volume
without destabilizing proteins.57 Our previous in vitro studies
using cultured human corneal epithelial cells demonstrated
that exogenous osmoprotectants L-carnitine (Garrett Q. IOVS
2012;53:ARVO E-Abstract 564; Willcox MD. IOVS 2012;53:AR-
VO E-Abstract 564) and betaine24 could help stabilize corneal
epithelial cell volume under hyperosmotic stress and limit
hyperosmotic stress–induced apoptosis. Among the com-
pounds tested, L-carnitine demonstrated the greatest ability.
It should be kept in mind though that the ICES marine model in
the present study represents only one form of dry-eye
condition that is induced environmentally. Whether the effects
of the osmoprotectants observed in the present study are
applicable to other forms of dry eye needs to be investigated.
Taken together, we conclude that systematic administration
of osmoprotectants L-carnitine, betaine, or erythritol can limit
progression and reduce the severity of environmentally
induced dry eye.
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